Prime Medicine, Inc.

Prime Medicine, Inc. is a biotechnology company that develops genetic medicines using its proprietary Prime Editing technology. This technology enables precise gene editing without causing double-stranded breaks in DNA. The company's lead product candidate is PM359 for Chronic Granulomatous Disease, currently in Phase 1/2 clinical trials. Its pipeline also includes PM577 for Wilson Disease (preclinical) and PM647 for a genetic disorder caused by SERPINA1 mutations leading to liver disease. Additionally, Prime Medicine has programs targeting liver diseases and Cystic Fibrosis. The company collaborates with BMS, the Cystic Fibrosis Foundation, the Broad Institute, and Beam.

Prime Medicine, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol PRME. Its shares are traded in US Dollars (USD), as the company is based in the United States. The exchange is a major US stock exchange, providing liquidity and visibility for investors.

Prime Medicine operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology firm, it focuses on developing genetic medicines using advanced gene editing technologies. The company's work involves research, preclinical studies, and clinical trials to address a range of diseases, including rare genetic disorders.

Prime Medicine is headquartered in Cambridge, Massachusetts, United States. The company primarily serves the US market, as indicated by its region classification as 'us'. Its operations and clinical trials are conducted in the United States, focusing on delivering genetic medicines to patients with various diseases.

Prime Medicine's business model centers on developing and commercializing genetic medicines using its Prime Editing platform. The platform includes a programmable DNA binding domain (Cas domain) and a reverse transcriptase (RT) domain that copies edited DNA sequences directly into the genome, along with a pegRNA that guides the editor to the target site. The company generates revenue through research collaborations and license agreements, such as its partnership with BMS. Its portfolio includes lead candidate PM359 for Chronic Granulomatous Disease, preclinical programs like PM577 for Wilson Disease, and PM647 for SERPINA1-related liver disease, as well as programs for Cystic Fibrosis and other liver conditions.